Constipation Drug May Slow Chronic Kidney Disease Progression

A common constipation medication may slow the progression of chronic kidney disease (CKD). Researchers at Tohoku University Graduate School of Medicine conducted a clinical trial. They found that lubiprostone, a drug used to treat constipation, helped preserve kidney function in patients with moderate CKD.

Chronic kidney disease affects millions globally. It is a leading cause of kidney failure. Many patients eventually require dialysis. Current treatments can slow damage, but no approved medications directly restore kidney function.

The study involved 150 patients with moderate CKD. Participants received either lubiprostone or a placebo. Patients receiving lubiprostone showed a slower decline in kidney function. This was measured by estimated glomerular filtration rate (eGFR). The protective effect appeared dose-dependent. Higher doses were linked to greater benefits.

Scientists investigated the mechanism behind this effect. Their analysis indicated changes in the gut microbiome. Lubiprostone increased the production of spermidine. Spermidine is a compound linked to healthier mitochondrial activity. Mitochondria are crucial for cellular energy production. Improved mitochondrial function may protect kidney tissue from damage. The treatment did not significantly reduce uremic toxins, which was an initial expectation.

Lubiprostone is an already approved medication for chronic constipation. This could accelerate its potential clinical use for CKD. Researchers are planning larger Phase three trials. These trials will confirm benefits in broader patient populations. They are also searching for biomarkers to predict patient response to treatment.

This discovery adds to the understanding of the gut-kidney axis. It highlights the connection between gut bacteria, cellular energy, and chronic disease. Slowing kidney decline could delay dialysis and improve quality of life for CKD patients.